Topic Archives: Novartis (NVS)

I got several reader questions this week about a new recommendation from Dave Lashmet at Stansberry — it looks like this was issued as a recommendation for regular Stansberry Investment Advisory subscribers, not one of Lashmet’s more expensive biotech-focused newsletters, and it’s very light on clues… but let’s see if we can give you anything […]

Please indulge Doc Gumshoe while he presents his musings on what’s going on in general in the health-care arena, and in particular, which new drugs are getting the FDA blessing and why, as well as which ones are getting the short straw.   My impressions and conclusions are in some cases only loosely based on […]

This article was originally published on March 21, 2019 when the “deadline” touted was March 25. We’ve lightly updated our piece below, but much of it (like the ad) is unchanged from March. The latest ad for Green Chip Stocks is a doozy — reminiscent of the many “the world is about to change” ads […]

Today we’ve got a teaser pitch from Marc Lichtenfeld to consider. It’s an ad for his Oxford Income Letter, but the “fountain of youth” pitch makes it sound like a wild ride of a biotech idea… so let’s dig in and see what we can find, shall we? Sometimes it’s best to start with the […]

Every now and then a reader sends in a question about one of the stock ideas teased by dividend.com, which is a service that looks for, you guessed it, dividend paying stocks. Their standard “tease” is that they send around some hints about the latest stock they’ve added to one of their “best” lists, but […]

We’ve seen a long stream of earnings reports and other worthwhile bits of data on Real Money Portfolio stocks since I last wrote to you, including some that actually included some interesting news, so prepare for a lot of quick updates…. Medical Properties Trust (MPW) reported another quarter of ho-hum… pretty much met the forecasts, […]

The article below was originally published on November 27, 2017, when Jeff Brown’s ads promoting the “God Key” started to show up in our inboxes. It has not been updated or revised, but the new versions of the ad from Brown are very similar to the ones we covered in November, including the description of […]

Remember Ernie Tremblay’s pitch about a “tiny South Texas lab” that was about to cure every disease using its revolutionary CD19 Cancer Vaccine technology, and ignite a bidding war following its fantastical release of exciting information on June 23? Well, it’s back. Not the stock, that’s still languishing around where it was before Tremblay got […]

[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends.  He does not typically write about specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]

[ed note: Michael Jorrin is longtime medical writer who has been sharing his thoughts with our readers as “Doc Gumshoe” for several years (he’s not a doctor, I gave him the name). He generally covers medical and health news and sometimes health promotions and hype, but he rarely opines about investments or specific stocks. All […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Ho ho ho! And Happy Christmas to all […]

[ed note: Michael Jorrin, who I like call “Doc Gumshoe,” is a longtime medical writer who shares his thoughts with us a couple times a month — his articles are non-financial in nature, his words and opinions are his own, and you can see his bio and his past pieces here. Enjoy!] Indulge me while […]

[Ed. Note: Dr. KSS writes for our Irregulars about medicine and biotech stocks. As always, he has agreed our trading restrictions, and his words and opinions are his own. You can find all of his previous articles here. And now, for some dim sum….] Greetings Irregulars, and welcome to Stock Gumshoe’s festive second BioDimSum shindig, a periodic round-up […]

[ed note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though, he mentions a couple publicly traded companies). His words and opinions are his own.] The […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Gumshoe Irregulars. He has agreed to our trading restrictions, he chooses his own topics, and his words and opinions are his own. Enjoy!] OK, admit it….how many of you have seen the campy films of Baltimore director John Waters? The ones starring the […]

[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars!  You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]

Comments

  • I owned Novartis (NVS) last year and did ok, but I got hit by a small foreign tax withholding, even in my IRA account. J...

  • Lubris BioPharma - Novartis $NVS - While searching this morning I found this article via Yahoo Finance: "Lubris BioPharm...

  • Serelaxin has failed in phase 3 for Novartis $NVS, a major blow to the company and to the field of heart failure managem...

  • Doc, there is another name that Rodman and Renshaw is also bullish on and you have made both positive and negative comme...

  • Novartis (NVS) touting 13 blockbuster's. https://endpts.com/fighting-a-generic-onslaught-novartis-adds-car-t-to-its-gr...

  • Novartis (NVS) in the hunt along with KITE for the first established CAR-T treatment to come to the market.It should be...

  • Novartis (NVS) thus far doing some impressive work with CTLO19 . https://www.novartis.com/news/media-releases/novarti...

  • Novartis (NVS) doing a big time new RD structure. http://endpts.com/novartis-unveils-a-new-global-rd-structure-with-n...

  • $CLCD long. Amgen ($AMGN) and Novartis’ ($NVS) migraine drug erenumab has hit the primary endpoint in a Phase II trial...

  • CRISPR/Cas9 company Intellia getting set for 140 million IPO with a 75 million partnership intact with Regeneron (REGN) ...

  • I closed out my position in Novartis $NVS today after several good years. The chart is broken after a sustained bull run...

  • Novartis (NVS) gets FDA approval of its new heart drug. http://www.forbes.com/sites/johnlamattina/2015/07/08/new-heart-...

  • $JUNO GOOD NEWS! Juno Investors Applaud End to Patent Fight -- Market Talk Cancer-drug developer JUNO gets a lif...

  • This Biotech (Aduro) put in for a IPO in March for 86 million and will be highly sought for after this deal with Novarti...

  • Nice interview about Novartis (NVS) drug LCZ696. http://www.medscape.com/viewarticle/838396?src=wnl_edit_specol Doc Ks...

  • Good Evening, greetings felllow boarders. Hard at work, you need a little diversion. By error I ended up buying EPR...

  • Thanks Dr. KSS. A-gain! Will hold off on $PFE, particularly as I keep pondering Novartis $NVS a company that, while valu...

  • Novartis (NVS) Farydak FDA approved for treatment of multiple mylenoma. http://www.fda.gov/NewsEvents/Newsroom/PressA...

  • Some "selected intelligence" relevant for several stocks of interest here: (1) Novartis $NVS. While this is a very la...

  • Glenn: I will have to do a little deeper digging on $IMUC, I am interested in it, but am trying to persuade myself that ...

  • Companies those working on RNA therapeutics, like Fierce Biotech broke the news that the Swiss giant, Novartis (NVS) was...

  • What effects (if any) can we expect from this development? Here are the lead paragraphs from the Novaratis announcement...

  • Does anyone have an opinion on whether LCZ696 has enough potential to seriously move the needle for Novartis (NVS)? The ...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info